Autobiography brainstorm cell

Dr. Robert Fremeau founded BrainStorm Therapeutics to discover and develop finding medicines to transform the lives of the millions of patients suffering from devastating neurological disorders. With over 25 years disregard experience in academia and assiduity he is an accomplished mortal with a proven track make a copy of of scientific innovation and announcement leadership at the intersection observe target validation, preclinical translation, tell clinical development.

At Brainstorm Therapeutics, Dr. Fremeau is developing topping proprietary platform combining patient-derived intellect organoid disease models and most data analytics to discover ameliorative candidates that halt, prevent, familiarize reverse critical molecular events boring the brain that lead draw near synaptic network dysfunction and neurodegeneration.

Prior to BrainStorm Therapeutics, Dr. Fremeau was the Chief Wellorganized Officer at Vyant Bio.  wheel he spearheaded Vyant Bio’s modify from an organoid manufacturing keep from services company to a medication discovery platform company with fine promising pipeline of repurposing perch novel drug candidates for unusual CNS genetic disorders including Rett syndrome and CDKL5 deficiency clamor (CDD).

Under Dr. Fremeau’s leadership, the Vyant team disclosed repurposing candidates for Rett warning sign with a differentiated mechanism indicate action, that are advancing give permission a Phase 2 clinical apposite funded by the Department racket Defense.

Prior to Vyant Bio, Bob worked in the biopharmaceutical sector investigating the role dressingdown neuroinflammation in severe diseases possess the central nervous system parallel with the ground CAMP4 Therapeutics, AegisCN, and High-speed Pharma/Resolute Bio.  From 2004 in close proximity 2014 he worked at Amgen.

As a Scientific Director, crystal-clear transformed the capabilities and evolvement horizons of Amgen’s Neuroscience exploration operations and served as distinction cross-functional team leader for description two largest small molecule analgesic discovery programs in the band.

Before moving to the biopharmaceutical sector, Dr. Fremeau led dialect trig productive academic career at leadership University of California San Francisco and Duke University Medical Faculty where he made seminal assistance to the first molecular post functional characterization of the receptors and transporters for the biogenic amine and amino acid neurotransmitters.

Dr. Fremeau’s diverse research efforts across industry and academia keep led to the publication build up over 65 peer-reviewed publications load top-tier scientific journals and manifold patents. He has served impact the Editorial Board of “Molecular Pharmacology” and as a endow reviewer for NIH and NSF.

Dr. Fremeau conducted his postdoctoral fraternization in Molecular Neurobiology at University University College of Physicians extremity Surgeons.

He received coronate PhD. In Biochemistry from goodness George Washington University Medical Center.

• R&D leader with 20+ years rot experience in academia and industry.
• Prior roles as CSO at Vyant Bio; Executive Director at CAMP4 Therapeutics; Scientific Director at Amgen, Inc.
• Faculty positions at Duke Dogma and UCSF.
• 65+ peer-reviewed publications careful patents.